TREATMENT ALGORITHM FOR IRON DEFICIENCY IN HEART FAILURE VERSION: Oktober 2015 REFERENCES: McMurray JJ et al. European Heart Journal 2012;33:1787-847. McMurray JJ et al. Eur J Heart Fail. 2012;14:803-69. Anker SD et al. Eur J Heart Fail. 2009;11:1084–91. Ponikowski P et al. European Heart Journal 2015 Mar 14;36(11):657-68. McDonagh T et al. Eur J Heart Fail. 2015 Mar;17(3):248-62. Iron deficiency is common in HF, it can lead to anaemia and/or skeletal muscle dysfunction, and has been associated with a worse prognosis. I.V. iron has been studied in patients with HFrEF and iron deficiency both with and without anaemia. More specifically, I.V. ferric carboxymaltose has been shown to improve self-reported patient global assessment, NYHA class, and exercise capacity. Treatment was also associated with a significant reduction in hospitalizations for worsening HF in the Confirm HF trial. However, no I.V. iron trial was powered to determine the impact on major outcomes, or to evaluate separately the effects in anaemic and non-anaemic patients. Finally, the effect of treating iron deficiency in HFpEF and the long-term safety of iron therapy in either HFrEF or HFpEF is unknown. http://bwghf.be